Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Prostatic Neoplasms: HELP
Michael K. Ong
Based on 9 articles published since 2010
(Why 9 articles?)
||||
Expertise Level
The expertise of Michael K. Ong ranks in the
  • Top 1.9%
  • ... of 145,674 published authors worldwide on Prostatic Neoplasms
  • ... from 2010 through 2020
  • ... based on contributions to 9 articles on the topic.
Graphical view (beta)
Aliases Ong, Michael K   ·   Ong, Michael   ·   Ong, M   ·   Ong, Mei-Sing
Work Locations
Details
Most likely:    Ottawa Hospital      
2019
  • The Institute of Cancer Research, Sutton, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK; University of Naples Federico II, Naples, Italy. · Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy. · The Institute of Cancer Research, Sutton, UK; Jules Bordet Institut, Brussels, Belgium. · The Royal Marsden NHS Foundation Trust, Sutton, UK. · The Ottawa Hospital Cancer Centre, Ottawa, Canada. · Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, University of Bern, Bern, Switzerland. · Santa Chiara Hospital, Trento, Italy. · Ospedale dell'Angelo Mestre, AULSS3 Serenissima, UOC Oncologia, Venice, Italy. · Monash University and Eastern Health, Box Hill, Australia. · Spanish National Cancer Research Center, Madrid, Spain. · Hospital Virgen de la Victoria, Malaga, Spain. · Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. · Jules Bordet Institut, Brussels, Belgium. · Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. · Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY, USA. · The Institute of Cancer Research, Sutton, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: · Pubmed 31307958
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. · The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute, Ottawa, ON, Canada. · Pubmed 30666463
2018
  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. · McMaster University and Ontario Clinical Oncology Group, Hamilton, ON, Canada. · Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. · Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. · Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. · Pubmed 29564623
2017
  • Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. · Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; University of Ottawa School of Epidemiology, Public Health and Preventative Medicine, Ottawa, Ontario, Canada. · The Ottawa Hospital, Ottawa, Ontario, Canada. · Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. Electronic address: · Pubmed 27554586
Probable:    University of Ottawa      
2019
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. · The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute, Ottawa, ON, Canada. · Pubmed 30666463
2018
  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. · McMaster University and Ontario Clinical Oncology Group, Hamilton, ON, Canada. · Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. · Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. · Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. · Pubmed 29564623
2017
  • Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. · Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; University of Ottawa School of Epidemiology, Public Health and Preventative Medicine, Ottawa, Ontario, Canada. · The Ottawa Hospital, Ottawa, Ontario, Canada. · Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. Electronic address: · Pubmed 27554586
Probable:    Harvard University Boston   Contact    
2017
  • From Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts. · Pubmed 28320011
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of all articles written by Michael K. Ong in 2010-2020 about Prostatic Neoplasms:

  • Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. 2019
  • The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. 2019
  • Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. 2018
  • A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. 2017
  • Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force Recommendation. 2017
  • Prostate Cancer Care Before and After Medicare Eligibility. 2016
  • AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. 2015
  • Novel drugs targeting the androgen receptor pathway in prostate cancer. 2014
  • Recent advances in second-line treatment of castration-resistant prostate cancer. 2011
Show List of Full Article Records
Google Searches

Learn more about Michael K. Ong using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Ottawa Hospital
University of Ottawa
Harvard University Boston
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Ottawa Hospital
2019
  • The Institute of Cancer Research, Sutton, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK; University of Naples Federico II, Naples, Italy. · Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy. · The Institute of Cancer Research, Sutton, UK; Jules Bordet Institut, Brussels, Belgium. · The Royal Marsden NHS Foundation Trust, Sutton, UK. · The Ottawa Hospital Cancer Centre, Ottawa, Canada. · Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, University of Bern, Bern, Switzerland. · Santa Chiara Hospital, Trento, Italy. · Ospedale dell'Angelo Mestre, AULSS3 Serenissima, UOC Oncologia, Venice, Italy. · Monash University and Eastern Health, Box Hill, Australia. · Spanish National Cancer Research Center, Madrid, Spain. · Hospital Virgen de la Victoria, Malaga, Spain. · Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. · Jules Bordet Institut, Brussels, Belgium. · Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. · Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY, USA. · The Institute of Cancer Research, Sutton, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: · Pubmed 31307958
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. · The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute, Ottawa, ON, Canada. · Pubmed 30666463
2018
  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. · McMaster University and Ontario Clinical Oncology Group, Hamilton, ON, Canada. · Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. · Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. · Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. · Pubmed 29564623
2017
  • Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. · Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; University of Ottawa School of Epidemiology, Public Health and Preventative Medicine, Ottawa, Ontario, Canada. · The Ottawa Hospital, Ottawa, Ontario, Canada. · Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. Electronic address: · Pubmed 27554586
University of Ottawa
2019
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. · The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute, Ottawa, ON, Canada. · Pubmed 30666463
2018
  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. · McMaster University and Ontario Clinical Oncology Group, Hamilton, ON, Canada. · Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. · Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. · Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada. · The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. · Pubmed 29564623
2017
  • Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada. · Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. · Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; University of Ottawa School of Epidemiology, Public Health and Preventative Medicine, Ottawa, Ontario, Canada. · The Ottawa Hospital, Ottawa, Ontario, Canada. · Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. Electronic address: · Pubmed 27554586
Harvard University Boston
2017
  • From Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts. · Pubmed 28320011
UCLA
2016
  • University of Southern California, Los Angeles, USA · University of California, Los Angeles, USA. · Pubmed 27166412
University of Western Ontario
2011
  • Division of Medical Oncology, Department of Oncology, University of Western Ontario, London, Ontario, Canada. · Pubmed 21734586
Royal Marsden Hospital and Trust
2015
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
University of London
2015
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
Yearly article counts 02121110010
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.